National Pension Service Has $12.08 Million Stock Holdings in Labcorp Holdings Inc. $LH

National Pension Service decreased its position in Labcorp Holdings Inc. (NYSE:LH) by 77.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 43,150 shares of the medical research company’s stock after selling 146,486 shares during the quarter. National Pension Service’s holdings in Labcorp were worth $12,082,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fifth Third Bancorp raised its stake in shares of Labcorp by 106.5% during the first quarter. Fifth Third Bancorp now owns 57,981 shares of the medical research company’s stock worth $15,470,000 after buying an additional 29,899 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Labcorp by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company’s stock valued at $534,023,000 after buying an additional 13,775 shares during the period. CIBC Asset Management Inc boosted its stake in Labcorp by 61.3% in the fourth quarter. CIBC Asset Management Inc now owns 19,974 shares of the medical research company’s stock valued at $5,011,000 after acquiring an additional 7,592 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Labcorp by 103.1% during the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock worth $1,343,922,000 after acquiring an additional 2,719,475 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in Labcorp by 125.2% during the 4th quarter. BNP Paribas Financial Markets now owns 253,352 shares of the medical research company’s stock worth $63,561,000 after acquiring an additional 140,869 shares during the period. 95.94% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reaffirmed its 2026 guidance of adjusted EPS of $18.10 to $18.55, broadly consistent with the analyst consensus of $18.32. Maintaining guidance supports confidence in near-term earnings visibility. Labcorp Holdings Reiterates 2026 Outlook, Issues Long-Term Guidance
• Positive Sentiment: The company issued a 2029 outlook calling for compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The targets imply sustained expansion beyond the current year and could support a higher long-term earnings outlook. Labcorp 2026 Investor Day Announcement
• Positive Sentiment: Labcorp plans to use artificial intelligence, specialty testing, scientific capabilities and global scale to drive growth. Management also emphasized strong cash-flow generation and disciplined capital deployment, which may improve shareholder returns if execution meets expectations. Labcorp Bets Big on AI and Specialty Testing
• Neutral Sentiment: The Investor Day transcript provided additional detail on Labcorp’s strategic priorities and long-term financial framework, but the benefits depend on successful implementation and investment in new technologies and testing capabilities. Labcorp Analyst and Investor Day Transcript
• Negative Sentiment: LH recently declined about 4.3% and underperformed peers, indicating that investors may have viewed the Investor Day information as insufficient to justify the stock’s elevated valuation or may have taken profits despite the favorable long-term targets. Labcorp Stock Heads Into the Open After a 4.3 Percent Slide

Labcorp Trading Up 1.4%

LH opened at $311.36 on Friday. The firm’s fifty day moving average is $310.39 and its two-hundred day moving average is $281.94. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. The firm has a market cap of $25.25 billion, a PE ratio of 25.75, a price-to-earnings-growth ratio of 1.77 and a beta of 0.88. Labcorp Holdings Inc. has a twelve month low of $244.52 and a twelve month high of $341.80.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The company had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.71 billion. During the same quarter in the previous year, the business earned $4.35 EPS. The firm’s revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Equities research analysts anticipate that Labcorp Holdings Inc. will post 18.32 EPS for the current year.

Labcorp Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 28th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Friday, August 28th. Labcorp’s payout ratio is presently 23.82%.

Insider Transactions at Labcorp

In other news, Director Kerrii B. Anderson sold 3,000 shares of Labcorp stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the transaction, the director owned 6,563 shares in the company, valued at $2,087,165.26. The trade was a 31.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 4,669 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the sale, the chief executive officer directly owned 102,565 shares of the company’s stock, valued at approximately $32,858,749.05. The trade was a 4.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 8,919 shares of company stock valued at $2,826,593. Insiders own 0.84% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. UBS Group increased their price target on Labcorp from $361.00 to $380.00 and gave the company a “buy” rating in a research note on Friday. Barclays lifted their price objective on Labcorp from $320.00 to $330.00 and gave the stock an “equal weight” rating in a research note on Friday. Piper Sandler upped their price objective on Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Bank of America increased their target price on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Truist Financial raised their target price on Labcorp from $320.00 to $350.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $336.36.

About Labcorp

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.